Ligand Pharmaceuticals (LGND) Net Margin (2010 - 2026)

Ligand Pharmaceuticals has disclosed Net Margin across 16 years of filings, most recently posting 25.8% for Q1 2026.

• Net Margin for Q1 2026 came in at 25.8%, up 6784.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 55.95% (up 9647.0% YoY), and the FY2025 annual result was 46.42%, up 4884.0% from the prior year.
• Net Margin came in at 25.8% for Q1 2026 at Ligand Pharmaceuticals, down from 75.06% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 101.57% in Q3 2025 to a low of 93.64% in Q1 2025.
• The 5-year median for Net Margin is 6.73% (2022), against an average of 5.83%.
• Across the five-year window, Net Margin tumbled 1967 bps in 2022 and soared 14767 bps in 2025, its largest moves.
• Ligand Pharmaceuticals' Net Margin stood at 5.86% in 2022, then jumped by 35 bps to 3.79% in 2023, then tumbled by 1818 bps to 72.62% in 2024, then jumped by 203 bps to 75.06% in 2025, then sank by 134 bps to 25.8% in 2026.
• The last three Net Margin figures came in at 25.8% (Q1 2026), 75.06% (Q4 2025), and 101.57% (Q3 2025), per Business Quant data.